[Effect of recombinant super-compound interferon (rSIFN-co) on human breast cancer cells in vitro].
OBJECTIVE
To study the anti-cancer activities of recombinant super-compound interferon (rSIFN-co) against human breast cancer cells, its cooperative anti-tumor effect with chemotherapy and the possible mechanism of these effects.


METHODS
The rSIFN-co, infergen, epirubicin were applied separately or combined in cultured human breast cancer cells MCF-7 and adriamycin-resistant strains of MCF-7/ADR cells. MTT assays and flow cytometry were applied to determine the growth inhibition and cell apoptosis index (AI) of MCF-7 and MCF-7/ ADR after different treatment. Immunohistochemical was used to detect the expression of P53, Bcl-2, CerbB-2 in treated MCF-7 and MCF-7/ADR cells.


RESULTS
The rSIFN-co demonstrated a efficiency of inhibiting the cell proliferation, induce apoptosis of both MCF-7 cells and MCF-7/ADR cells, which was stronger than that of infergen in the same concentration; rSIFN-co combined with epirubicin has a synergistic action in inhibiting cell proliferation, inducing apoptosis of both type of breast cancer cells; rSIFN-co can also decrease the expression level of P53 and CerbB-2, increase the expression of Bcl-2 in both cell lines.


CONCLUSIONS
In vitro conditions, rSIFN-co can inhibit cell growth of human breast cancer cell MCF-7 and MCF-7/ADR, which may attribute to influence the proliferation-associated factor expression, and induce apoptosis of cancer cells.
Zheng
Jie
J
Department of Thyroid and Breast Surgery, West China Hospital , Sichuan University, Chengdu 610041, China.
Lü
Qing
Q
Wei
Da-Peng
DP
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004357:Drug Synergism; D015251:Epirubicin / Q000494:pharmacology; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology; D016898:Interferon-alpha; D007371:Interferon-gamma / Q000494:pharmacology*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015251:Epirubicin; C050739:interferon alfacon-1; D007371:Interferon-gamma